{"altmetric_id":2525849,"counts":{"readers":{"mendeley":12,"citeulike":0,"connotea":0},"blogs":{"unique_users_count":1,"unique_users":[53252],"posts_count":1},"total":{"posts_count":3},"twitter":{"unique_users_count":2,"unique_users":["CO_Pulmonary_Md","danirossmm"],"posts_count":2}},"citation":{"abstract":"Although early pulmonary revascularization is the treatment of choice for patients with high-risk (massive) pulmonary embolism, it remains controversial in patients with intermediate-risk (submassive) pulmonary embolism until recently. Recent published data on the management of high-risk and intermediate-risk pulmonary embolism patients will be the main focus of this review.","abstract_source":"pubmed","altmetric_jid":"4f6fa5e63cf058f61000586c","authors":["Sanchez O","Planquette B","Meyer G"],"doi":"10.1097\/mcp.0000000000000089","first_seen_on":"2014-07-21T12:32:24+00:00","issns":["1070-5287"],"issue":"","journal":"Current opinion in pulmonary medicine","last_mentioned_on":1409339235,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25029299","http:\/\/journals.lww.com\/co-pulmonarymedicine\/Abstract\/2014\/09000\/Management_of_massive_and_submassive_pulmonary.2.aspx"],"pmid":"25029299","pubdate":"2014-07-18T00:00:00+00:00","scopus_subjects":["Medicine","Health Sciences"],"subjects":["pulmonarymedicine"],"title":"Management of massive and submassive pulmonary embolism: focus on recent randomized trials","type":"article","volume":"","mendeley_url":"http:\/\/www.mendeley.com\/research\/management-massive-submassive-pulmonary-embolism"},"altmetric_score":{"score":8,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":8},"context_for_score":{"all":{"total_number_of_other_articles":4507509,"mean":5.1386389830674,"rank":505171,"this_scored_higher_than_pct":88,"this_scored_higher_than":3991555,"rank_type":"exact","sample_size":4507509,"percentile":88},"similar_age_3m":{"total_number_of_other_articles":109917,"mean":7.9936836857238,"rank":15280,"this_scored_higher_than_pct":85,"this_scored_higher_than":94421,"rank_type":"exact","sample_size":109917,"percentile":85},"this_journal":{"total_number_of_other_articles":365,"mean":2.2333681318681,"rank":17,"this_scored_higher_than_pct":95,"this_scored_higher_than":348,"rank_type":"exact","sample_size":365,"percentile":95},"similar_age_this_journal_3m":{"total_number_of_other_articles":35,"mean":1.5919411764706,"rank":2,"this_scored_higher_than_pct":94,"this_scored_higher_than":33,"rank_type":"exact","sample_size":35,"percentile":94}}},"demographics":{"poster_types":{"member_of_the_public":2},"users":{"twitter":{"cohorts":{"Members of the public":2}},"mendeley":{"by_status":{"Researcher":3,"Student  > Postgraduate":3,"Other":4,"Student  > Master":1,"Student  > Bachelor":1},"by_discipline":{"Design":1,"Medicine and Dentistry":10,"Unspecified":1}}}},"posts":{"blogs":[{"title":"The Normotensive Pulmonary Embolism Patient","url":"http:\/\/www.sinaiem.org\/pearls\/2014\/07\/21\/thenormotensivepulmonaryembolismpatient\/","citation_ids":[2525849],"posted_on":"2014-07-21T00:09:00+00:00","summary":"Early death (within 7-30 days) in PE patients is concerning. It is relatively easy to identify high-risk PE patients, defined by abnormal vitals SBP &lt; 90 or drop in SBP by 40 for at least 5 min.\nNormotensive patients with poor prognostic indicators incl","author":{"name":"FOAM EM RSSFOAM EM RSS","url":"http:\/\/www.foamem.com","description":"Free Open Access Medical Education"}}],"twitter":[{"url":"https:\/\/twitter.com\/CO_Pulmonary_Md\/status\/500989773163413505","license":"datasift","citation_ids":[2525849],"posted_on":"2014-08-17T12:57:24+00:00","author":{"name":"CO Pulmonary Med","url":"http:\/\/www.co-pulmonarymedicine.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1706276488\/MCP_square_cover_normal.jpg","description":"Provides powerful perspectives on the most important advances in published literature, delivering expert assessments of developments from the previous year.","id_on_source":"CO_Pulmonary_Md","tweeter_id":"368365405","geo":{"lt":null,"ln":null},"followers":252},"tweet_id":"500989773163413505"},{"url":"https:\/\/twitter.com\/danirossmm\/status\/505431504428998656","license":"datasift","rt":["CO_Pulmonary_Md"],"citation_ids":[2525849],"posted_on":"2014-08-29T19:07:15+00:00","author":{"name":"Dani-Ross Monserrate","image":"https:\/\/pbs.twimg.com\/profile_images\/525967476740599808\/iRp4svWI_normal.jpeg","description":"MD Respiratory and Sleep Medicine, Clinical Trials, PFT, Asthma, COPD, TB","id_on_source":"danirossmm","tweeter_id":"634926828","geo":{"lt":null,"ln":null},"followers":210},"tweet_id":"505431504428998656"}]}}